Home / Leaderboard / Farallon Capital Management, L.L.C.
Farallon Capital Management, L.L.C.
Nicolas Giauque · Hedge Fund · Multi-Strategy
Farallon Capital Management, L.L.C. is a global institutional asset management firm headquartered in San Francisco, California. Founded in 1986 by Thomas Steyer, the firm has evolved into one of the world's largest alternative asset managers, employing hundreds of professionals across major global financial hubs. Farallon utilizes a multi-strategy approach, investing opportunistically across diverse asset classes including credit, equities, real estate, and merger arbitrage. The firm primarily manages capital for sophisticated institutional investors, such as university endowments, charitable foundations, and pension plans. With nearly four decades of history, Farallon is recognized for its commitment to capital preservation and its rigorous, research-intensive investment process.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +44.7% |
| YTD return | +25.7% |
| Sharpe ratio | 3.82 |
| Win rate | 49% |
| AUM | $12.8B |
| Inception | Oct 1, 2025 |
| Updated | Oct 2, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $12.8B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.faralloncapital.com |
Current Holdings
Updated on Oct 2, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| RVMD | Revolution Medicines Inc | 20.0% | +82.6% |
| PTGX | Protagonist Therapeutics Inc | 7.1% | +53.8% |
| EXEL | Exelixis Inc | 6.3% | +28.1% |
| NTRA | Natera Inc | 6.2% | +120.4% |
| BBIO | BridgeBio Pharma Inc | 5.6% | +4.2% |
| TMO | Thermo Fisher Scientific Inc | 5.3% | +20.0% |
| AMZN | Amazon.com Inc | 5.2% | +7.7% |
| ROIV | Roivant Sciences Ltd | 4.5% | +2.1% |
| LNTH | Lantheus Holdings Inc | 4.4% | +19.9% |
| LQDA | Liquidia Technologies Inc | 4.4% | -47.0% |
| MSFT | Microsoft Corporation | 4.3% | +10.3% |
| UNH | UnitedHealth Group Incorporated | 3.7% | +6.3% |
| BSX | Boston Scientific Corp | 3.6% | -12.6% |
| AVGO | Broadcom Inc | 3.2% | -15.2% |
| AON | Aon PLC | 3.2% | -20.6% |
| KKR | KKR & Co LP | 3.2% | -7.4% |
| TWST | Twist Bioscience Corp | 2.7% | +13.0% |
| GRAL | GRAIL, LLC | 2.6% | +79.4% |
| SNPS | Synopsys Inc | 2.5% | +7.8% |
| TNGX | Tango Therapeutics Inc | 2.1% | +3.2% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Sep 21, 2026 | BUY | TMO | 4.9% → 5.3% |
| Sep 21, 2026 | SELL | LQDA | 4.4% → 4.4% |
| Sep 21, 2026 | SELL | RVMD | 21.2% → 20.0% |
| Sep 21, 2026 | SELL | CMPGY | 2.1% → 0.0% |
| Sep 21, 2026 | SELL | KKR | 3.2% → 3.2% |
Investment Style Analysis
Farallon Capital Management, L.L.C. is widely recognized for employing a Multi-Strategy strategy. As of Oct 2, 2026, the firm oversees approximately $12.8B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Diagnostics & Research sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Sep 21, Farallon Capital Management, L.L.C. made a significant move by increasing exposure to TMO. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Farallon Capital Management follows a flexible, multi-strategy investment philosophy focused on achieving superior risk-adjusted returns through bottom-up fundamental analysis. The firm's approach is opportunistic and global, spanning credit, long/short equity, merger arbitrage, real estate, and direct investments. Farallon emphasizes capital preservation and disciplined risk management, allowing capital to compete across strategies based on in-depth assessments of specific risks and rewards. The investment process is characterized by a collaborative, team-based structure and a commitment to aligning interests with long-term investors by maintaining a stable, partner-owned organizational framework.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Farallon Capital Management, L.L.C..
Similar Investment Style
Based on Multi-Strategy.
- Sandoz Family Office SA — Marc Duc · 3M -10.0%
- BB Gestão de Recursos - Distribuidora de Títulos e Valores Mobiliários S.A. — Denísio Liberato · 3M +8.0%
- Wolverine Trading, LLC — Robert Bellick · 3M +6.8%
- Amundi Asset Management US, Inc. — Marco Pirondini · 3M -1.5%
Frequently asked questions
How is the simulated portfolio for Farallon Capital Management, L.L.C. constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Farallon Capital Management, L.L.C.'s largest holding?
As of the latest filing, Farallon Capital Management, L.L.C.'s top position is Revolution Medicines Inc (RVMD), representing 20.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Farallon Capital Management, L.L.C.'s historical performance and risk profile?
Our simulation indicates a total return of +44.7% with a win rate of 49%. Notably, the portfolio maintains a Sharpe Ratio of 3.82, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Farallon Capital Management, L.L.C. primarily invest in?
Farallon Capital Management, L.L.C. has a strong preference for the Biotechnology sector, which makes up 50.0% of their disclosed assets. The portfolio also has exposure to Diagnostics & Research, indicating a specific thematic focus.
Is Farallon Capital Management, L.L.C.'s portfolio concentrated or diversified?
Farallon Capital Management, L.L.C. runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 33.4% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Farallon Capital Management, L.L.C. performed in 2026?
Our AI-simulated model portfolio for Farallon Capital Management, L.L.C. tracks a Year-to-Date (YTD) return of +25.7%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Nicolas Giauque manage Farallon Capital Management, L.L.C. directly?
Yes, Nicolas Giauque serves as the key portfolio manager for Farallon Capital Management, L.L.C., overseeing the investment strategy and final capital allocation decisions.